Cardiology

Corrected QT Interval (QTc) Calculator: Bazett, Fridericia, Framingham, Hodges, and Rautaharju 

<a href="https://endcalc.com/?p=109">Corrected QT</a> Interval (QTc) Calculator

Unauthorized Use Detected

This tool is only available at endcalc.com. Please visit the original site to use this calculator.

Evidence-Based Clinical Tool

Corrected QT Interval

Calculates QTc using all five major correction formulas: Bazett, Fridericia, Framingham, Hodges, and Rautaharju.

Used to identify QT prolongation — a risk factor for torsades de pointes and sudden cardiac death — particularly when initiating QT-prolonging drugs, monitoring electrolyte disturbances, or evaluating congenital long QT syndrome. Multiple formulas are compared simultaneously to aid clinical interpretation.

Formulas
Bazett: QT / √RR Fridericia: QT / RR^⅓ Framingham: QT + 154×(1−RR) Hodges: QT + 1.75×(HR−60) Rautaharju: QT×(120+HR)/180
QT Interval
small squares
Count small squares from Q onset to end of T wave (1 sq = 40 ms at 25 mm/s)
Input as
sq
5 sq17.5 sq
Heart Rate
bpm
Ventricular rate from ECG or pulse oximetry
bpm
30200 bpm
Biological Sex
For threshold reference
QTc prolongation thresholds differ by sex (ACC/AHA guidelines)
Enter QT interval and heart rate to calculate QTc
QTc (ms)SexClassificationClinical Significance
< 440 Male Normal No QT prolongation
< 460 Female Normal No QT prolongation
440 – 459 Male Borderline Monitor; review QT-prolonging medications
460 – 479 Female Borderline Monitor; review QT-prolonging medications
≥ 500 Both Markedly Prolonged High TdP risk; consider stopping offending drug

TdP = Torsades de Pointes. Prolongation thresholds: males ≥440 ms (borderline), ≥500 ms (high risk); females ≥460 ms (borderline), ≥500 ms (high risk). Per ACC/AHA 2009 guidelines.

1
Bazett overcorrects at high heart rates The Bazett formula (QT/√RR) is the most widely used but systematically overcorrects at heart rates above 80–90 bpm, producing falsely elevated QTc values in tachycardia, and undercorrects at very low heart rates (<50 bpm). It was derived from a small dataset and remains prevalent primarily due to historical inertia. For patients with tachycardia, Fridericia or Framingham are more appropriate.
2
Formula selection affects clinical decision-making The five formulas can produce materially different QTc values for the same patient — differences of 20–40 ms are not unusual, especially at heart rates far from 60 bpm. When a borderline result is obtained with one formula, applying others adds important context. No single formula is universally superior; institutional or drug-trial protocols often specify which formula to use.
3
Accurate QT measurement is the most critical variable All correction formulas are only as accurate as the raw QT measurement. The most common errors include: (1) including the U wave in the QT measurement, (2) measuring from the wrong lead (leads II and V5 typically show the longest measurable QT), and (3) inconsistent identification of the T wave end, especially with broad, biphasic, or notched T waves. Manual calipers and the tangent method are recommended for precision.
4
Electrolyte disturbances directly affect QT independent of heart rate Hypokalaemia, hypomagnesaemia, and hypocalcaemia are among the most common causes of acquired QT prolongation and increase TdP risk independent of the QTc value. Electrolytes should always be checked and corrected before attributing QT prolongation to drugs alone. A corrected QTc of 480 ms with potassium of 3.0 mEq/L carries different risk than the same QTc with normal electrolytes.
5
QTc in atrial fibrillation requires special handling In atrial fibrillation, the RR interval varies beat to beat. A single HR-derived RR interval may not accurately represent the cardiac cycle. The standard approach is to measure QT across multiple beats and average the results, or use the mean RR interval over several cycles. Some guidelines recommend measuring QT following the longest and shortest preceding RR intervals and averaging the QTc values.
6
QTc thresholds are not absolute risk cutoffs A QTc of 499 ms does not carry meaningfully different TdP risk than 501 ms. The thresholds (440/460 ms, 500 ms) are derived from population studies and represent increased risk zones, not binary safe/unsafe cutoffs. Risk stratification should integrate QTc with concomitant QT-prolonging drugs, electrolytes, genetic predisposition, structural heart disease, and rate of QT change over time.
7
Congenital long QT syndrome may present with a normal resting QTc Approximately 25–40% of genotypically confirmed LQTS patients have a resting QTc within the normal range. Provocative testing (exercise, epinephrine infusion), genetic testing, and family history remain essential for diagnosis. A “normal” QTc on this calculator does not rule out congenital LQTS, particularly if the clinical context suggests it.
Bazett HC. An analysis of the time-relations of electrocardiograms. Heart. 1920;7:353–370.
Fridericia LS. The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. Acta Med Scand. 1920;53:469–486.
Sagie A, et al. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol. 1992;70(7):797–801.
Hodges M, et al. Bazett’s QT correction reviewed. Evidence that a linear QT correction for heart rate is better. J Am Coll Cardiol. 1983;1(2):694.
Rautaharju PM, et al. Assessment of prolonged QT and JT intervals in ventricular conduction defects. Am J Cardiol. 1994;73(9):672–677.
Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013–1022.

This calculator is provided for educational and informational purposes only. QTc results should always be interpreted in full clinical context including medications, electrolytes, and patient history. Do not make clinical decisions based solely on this tool. Consult a qualified clinician or cardiologist for management of QT prolongation.

Reviewed by ·
Semahattin Serkan Sezer MD

Pulmonologist and Intensive Care Specialist specializing in clinical informatics and the development of evidence-based decision support tools for healthcare professionals.